Trial Profile
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Betibeglogene-autotemcel (Primary)
- Indications Sickle cell anaemia
- Focus Registrational; Therapeutic Use
- Sponsors bluebird bio
- 08 Feb 2024 Status changed from active, no longer recruiting to completed.
- 12 Dec 2023 Results (N=47, HGB-206 Group C, n=36; HGB-210, n=11)of pooled analysis (NCT02140554 and NCT04293185) assessing efficacy and safety from these studies, including the first data from adult and pediatric patients (age 12 to <18 years) in HGB-210, and HRQOL data from HGB-206, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 09 Dec 2023 According to a bluebird bio media release, analysis (n=47) of data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies were highlighted in a press briefing at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition and will be presented in an oral presentation on Monday, December 11, 2023 at 4:30 p.m. Pacific Time.